28 50

Cited 0 times in

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer

DC FieldValueLanguage
dc.contributor.author김상운-
dc.contributor.author김성훈-
dc.contributor.author김영태-
dc.contributor.author남은지-
dc.contributor.author박준식-
dc.contributor.author어경진-
dc.contributor.author이정윤-
dc.date.accessioned2020-12-01T17:47:27Z-
dc.date.available2020-12-01T17:47:27Z-
dc.date.issued2020-04-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180453-
dc.description.abstractPurpose: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improve clinical outcomes without affecting safety. Materials and methods: We retrospectively reviewed medical records of patients with pathologically confirmed ovarian cancer who received neoadjuvant chemotherapy (NAC) at Yonsei Cancer Hospital. We divided the patients into groups based on the use of bevacizumab for NAC (CP group: carboplatin+paclitaxel vs. BCP group: bevacizumab+carboplatin+paclitaxel) and compared patient characteristics, responses to NAC, and surgical and survival outcomes between the two groups. Overall, 88 patients in the CP group and 16 patients in the BCP group received NAC. The primary endpoint was survival outcomes. Complete resection rate after interval debulking surgery (IDS), cancer antigen 125 (CA-125) normalization after NAC, and chemotherapy response score were secondary endpoints. Results: After NAC treatment, all patients underwent IDS. There were no significant differences in adverse events during NAC or postoperative complications between the two groups (p=0.293 and p=0.485, respectively). There were also no significant differences in CA-125 normalization after NAC (42.0% vs. 43.8%, p=0.899) or complete resection rate after IDS (47.7% vs. 56.3%, p=0.530). However, although the BCP group did not show longer overall survival (OS) (log-rank p=0.854), they had significantly longer progression-free survival (PFS) than the CP group (log-rank p=0.048). Conclusion: Bevacizumab-containing NAC might be safe and provide longer PFS than chemotherapy alone in patients with advanced ovarian cancer. However, further study is necessary to investigate the impact of bevacizumab-containing NAC on OS.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use*-
dc.subject.MESHBevacizumab / administration & dosage-
dc.subject.MESHBevacizumab / therapeutic use*-
dc.subject.MESHCA-125 Antigen-
dc.subject.MESHCarboplatin / administration & dosage-
dc.subject.MESHCarboplatin / therapeutic use-
dc.subject.MESHCarcinoma, Ovarian Epithelial / mortality-
dc.subject.MESHCarcinoma, Ovarian Epithelial / pathology-
dc.subject.MESHCarcinoma, Ovarian Epithelial / therapy*-
dc.subject.MESHCytoreduction Surgical Procedures / adverse effects-
dc.subject.MESHCytoreduction Surgical Procedures / mortality-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOvarian Neoplasms / mortality-
dc.subject.MESHOvarian Neoplasms / pathology-
dc.subject.MESHOvarian Neoplasms / therapy*-
dc.subject.MESHPaclitaxel / administration & dosage-
dc.subject.MESHPaclitaxel / therapeutic use-
dc.subject.MESHPostoperative Complications-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Outcome-
dc.titleA Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorJunsik Park-
dc.contributor.googleauthorKyung Jin Eoh-
dc.contributor.googleauthorEun Ji Nam-
dc.contributor.googleauthorSunghoon Kim-
dc.contributor.googleauthorSang Wun Kim-
dc.contributor.googleauthorYoung Tae Kim-
dc.contributor.googleauthorJung Yun Lee-
dc.identifier.doi10.3349/ymj.2020.61.4.284-
dc.contributor.localIdA00526-
dc.contributor.localIdA00595-
dc.contributor.localIdA00595-
dc.contributor.localIdA00729-
dc.contributor.localIdA00729-
dc.contributor.localIdA01262-
dc.contributor.localIdA01262-
dc.contributor.localIdA05788-
dc.contributor.localIdA05788-
dc.contributor.localIdA04842-
dc.contributor.localIdA04842-
dc.contributor.localIdA04638-
dc.contributor.localIdA04638-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid32233170-
dc.subject.keywordBevacizumab-
dc.subject.keywordepithelial ovarian cancer-
dc.subject.keywordinterval debulking surgery-
dc.subject.keywordneoadjuvant chemotherapy-
dc.contributor.alternativeNameKim, Sang Wun-
dc.contributor.affiliatedAuthor김상운-
dc.contributor.affiliatedAuthor김성훈-
dc.contributor.affiliatedAuthor김성훈-
dc.contributor.affiliatedAuthor김영태-
dc.contributor.affiliatedAuthor김영태-
dc.contributor.affiliatedAuthor남은지-
dc.contributor.affiliatedAuthor남은지-
dc.contributor.affiliatedAuthor박준식-
dc.contributor.affiliatedAuthor박준식-
dc.contributor.affiliatedAuthor어경진-
dc.contributor.affiliatedAuthor어경진-
dc.contributor.affiliatedAuthor이정윤-
dc.contributor.affiliatedAuthor이정윤-
dc.citation.volume61-
dc.citation.number4-
dc.citation.startPage284-
dc.citation.endPage290-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.61(4) : 284-290, 2020-04-
dc.identifier.rimsid67528-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.